Cargando…

Fibrosis regression following hepatitis C antiviral therapy

Hepatitis C virus (HCV) infection is one of the most common causes of liver pathology. It is a major etiological factor of continuous liver injury by triggering an uncontrolled inflammatory response, causing liver fibrosis and cirrhosis. Liver fibrosis is a dynamic process that can be reversible upo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Elsharkawy, Aisha, Samir, Reham, El-Kassas, Mohamed
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2022
Materias:	Minireviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9258254/ https://www.ncbi.nlm.nih.gov/pubmed/35978676 http://dx.doi.org/10.4254/wjh.v14.i6.1120

Ejemplares similares

Metabolic aspects of hepatitis C virus
por: El-Kassas, Mohamed, et al.
Publicado: (2022)

Towards hepatitis C virus elimination: Egyptian experience, achievements and limitations
por: Omran, Dalia, et al.
Publicado: (2018)

Discontinuation of antiviral therapy in chronic hepatitis B patients
por: Medas, Renato, et al.
Publicado: (2021)

Impact of modern antiviral therapy of chronic hepatitis B and C on clinical outcomes of liver disease
por: Khoo, Tiffany, et al.
Publicado: (2021)

Hepatitis C-related hepatocellular carcinoma in the era of new generation antivirals
por: Baumert, Thomas F., et al.
Publicado: (2017)

Hepatocellular carcinoma after direct-acting antiviral hepatitis C virus therapy: A debate near the end
por: Muzica, Cristina Maria, et al.
Publicado: (2020)

Hepatitis C Antiviral Therapy In Patients With Successfully Treated Hepatocellular Carcinoma: Dancing With Wolves
por: El Kassas, Mohamed, et al.
Publicado: (2019)

Use of direct-acting antiviral agents in hepatitis C virus-infected liver transplant candidates
por: Gadiparthi, Chiranjeevi, et al.
Publicado: (2018)

Incidental radiological findings suggestive of COVID-19 in asymptomatic patients
por: Romeih, Marwa, et al.
Publicado: (2022)

Direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C: A few lights and many shadows
por: Guarino, Maria, et al.
Publicado: (2018)

Challenges in the discontinuation of chronic hepatitis B antiviral agents
por: Kaewdech, Apichat, et al.
Publicado: (2021)

Tumor characteristics of hepatocellular carcinoma after direct-acting antiviral treatment for hepatitis C: Comparative analysis with antiviral therapy-naive patients
por: Fouad, Magdy, et al.
Publicado: (2021)

Patterns of liver profile disturbance in patients with COVID-19
por: Shousha, Hend Ibrahim, et al.
Publicado: (2022)

Retreatment of patients with treatment failure of direct-acting antivirals: Focus on hepatitis C virus genotype 1b
por: Kanda, Tatsuo, et al.
Publicado: (2017)

Antiviral treatment for chronic hepatitis B: Safety, effectiveness, and prognosis
por: Wu, Ya-Li, et al.
Publicado: (2019)

Safety of direct acting antiviral treatment for hepatitis C in oncologic setting: A clinical experience and a literature review
por: Spera, Anna Maria
Publicado: (2022)

Elastography as a predictor of liver cirrhosis complications after hepatitis C virus eradication in the era of direct-acting antivirals
por: Cerrito, Lucia, et al.
Publicado: (2021)

Association between direct-acting antiviral agents in hepatitis C virus treatment and hepatocellular carcinoma occurrence and recurrence: The endless debate
por: Kamal, Ahmed, et al.
Publicado: (2022)

Direct antiviral agents in hepatitis C virus related liver disease: Don’t count the chickens before they’re hatched
por: Compagnoni, Stella, et al.
Publicado: (2021)

Egy-Score as a Noninvasive Score for the Assessment of Hepatic Fibrosis in Chronic Hepatitis C: A Preliminary Approach
por: Alboraie, Mohamed, et al.
Publicado: (2014)

Expanding antiviral therapy indications for HBeAg-negative chronic hepatitis B patients with normal ALT and positive HBV DNA
por: Zhou, Jing, et al.
Publicado: (2022)

Pathophysiological mechanisms of hepatic stellate cells activation in liver fibrosis
por: Garbuzenko, Dmitry Victorovich
Publicado: (2022)

Challenge of managing hepatitis B virus and hepatitis C virus infections in resource-limited settings
por: Said, Zeinab Nabil Ahmed, et al.
Publicado: (2022)

Non-pulmonary involvement in COVID-19: A systemic disease rather than a pure respiratory infection
por: El-Kassas, Mohamed, et al.
Publicado: (2023)

Effect of treating chronic hepatitis C with direct-acting antivirals on extrahepatic cutaneous manifestations
por: El Kassas, Mohamed, et al.
Publicado: (2020)

Target Discovery for Host-Directed Antiviral Therapies: Application of Proteomics Approaches
por: Cakir, Merve, et al.
Publicado: (2021)

Progression and status of antiviral monitoring in patients with chronic hepatitis B: From HBsAg to HBV RNA
por: Liu, Ya-Yun, et al.
Publicado: (2018)

Long-term liver allograft fibrosis: A review with emphasis on idiopathic post-transplant hepatitis and chronic antibody mediated rejection
por: Vij, Mukul, et al.
Publicado: (2022)

New era for management of chronic hepatitis C virus using direct antiviral agents: A review
por: Elbaz, Tamer, et al.
Publicado: (2015)

Metabolic and cardiovascular complications after virological cure in hepatitis C: What awaits beyond
por: Shengir, Mohamed, et al.
Publicado: (2021)

The challenges and promises of new therapies for cystic fibrosis
por: Pier, Gerald B.
Publicado: (2012)

Regression in hepatic fibrosis in elderly Chinese patients with hepatitis C receiving direct-acting antiviral treatment
por: Niu, Bin, et al.
Publicado: (2023)

Management of hepatitis B and C in special population
por: Kulkarni, Anand V, et al.
Publicado: (2021)

Impact of coronavirus disease 2019 on prevention and elimination strategies for hepatitis B and hepatitis C
por: Rehman, Syed Tabish, et al.
Publicado: (2021)

Hepatic epithelioid hemangioendothelioma: Update on diagnosis and therapy
por: Kou, Kai, et al.
Publicado: (2020)

Accelerating the elimination of hepatitis C in Kuwait: An expert opinion
por: Hasan, Fuad, et al.
Publicado: (2020)

Neurological and psychiatric effects of hepatitis C virus infection
por: Faccioli, Jessica, et al.
Publicado: (2021)

Advances in the Development of Antiviral Compounds for Rotavirus Infections
por: Tohmé, María Julieta, et al.
Publicado: (2021)

Hepatitis C infection in Egypt: prevalence, impact and management strategies
por: Gomaa, Asmaa, et al.
Publicado: (2017)

Spontaneous regression of hepatocellular carcinoma: A mini-review
por: Sakamaki, Akira, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_7i048urmcuatt5793b4482oghs